Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments

The pharmacological treatment of cognitive impairments associated with schizophrenia is still a major unmet clinical need. Indeed, treatments with available antipsychotics generate highly variable cognitive responses among patients with schizophrenia. This has led to the general assumption that anti...

Descripció completa

Dades bibliogràfiques

Autors principals:	Sebastiano Alfio Torrisi, Samuele Laudani, Gabriella Contarini, Angelina De Luca, Federica Geraci, Francesca Managò, Francesco Papaleo, Salvatore Salomone, Filippo Drago, Gian Marco Leggio
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2020-11-01
Col·lecció:	Pharmaceuticals
Matèries:	cognition schizophrenia dopamine receptors second-generation antipsychotics
Accés en línia:	https://www.mdpi.com/1424-8247/13/11/365
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!